Leslie D. Funtleyder - Jun 15, 2021 Form 4 Insider Report for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Role: Director
Signature: /s/ Narayan Prabhu, attorney-in-fact for Leslie Funtleyder
Stock symbol: RVPH
Transactions as of: Jun 15, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/16/2021, 04:30 PM
Previous filing: Jun 4, 2021
Next filing: Dec 10, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVPH	Stock Option (right to buy)	Award	$0	+4K		$0.00	4K	Jun 15, 2021	Common Stock, par value $0.0001 per share	4K	$4.73	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

Content

The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.